Exploring the molecular mechanisms of uterine sarcoma
Molecular Mechanism Study of Uterine Sarcoma
This study is trying to find out what causes uterine sarcoma and how it develops, to help improve diagnosis and treatment for patients with this rare cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | Female |
| Sponsor | Tongji Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT05881967 on ClinicalTrials.gov |
What this trial studies
This project aims to utilize multi-omics technology to identify key factors involved in the occurrence and progression of uterine sarcoma, particularly focusing on uterine leiomyosarcoma. Uterine sarcomas are rare tumors with poor prognosis, and the study seeks to enhance diagnostic classification and prognostication through molecular characterization. By mapping the interaction networks of cell signaling pathways, the research intends to uncover potential diagnostic biomarkers that could improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 18 or older who have newly treated or recurrent uterine sarcoma.
Not a fit: Patients with a history of other malignancies within the past 5 years or those who have undergone pelvic or vaginal radiation therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic tools and targeted therapies for patients with uterine sarcoma.
How similar studies have performed: While the approach of using multi-omics technology is gaining traction, the specific application to uterine sarcoma is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18 or older; 2. Newly treated or recurenced uterine sarcoma. Exclusion Criteria: 1. Diagnosis of other malignancies within the past 5 years; 2. history of pelvic or vaginal radiation therapy; 3. Known high-grade lesions of the cervix and endometrium.
Where this trial is running
Wuhan, Hubei
- Yan Li — Wuhan, Hubei, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.